Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent.Tokyo, Japan, Dec 27, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kissei Pharmaceutical and JCR JCR Journal Citation Reports JCR Java Content Repository (IBM) JCR Junior Common Room (British university term) JCR Journal of Clinical Rheumatology JCR Journal of Circadian Rhythms Pharmaceuticals have jointly announced that they have singed a joint research agreement for JR-013, a compound candidate discovered by JCR Pharmaceuticals. JR-013 is a drug candidate for the treatment of renal anemia based on recombinant human erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production . Under the agreement terms, Kissei Pharmaceutical will make milestone payments to JCR Pharmaceuticals while being licensed to sell the agent in Japan. The phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for JR-013 started in November. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion